Loading…
Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function
Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in huma...
Saved in:
Published in: | Nephrology, dialysis, transplantation dialysis, transplantation, 2010-10, Vol.25 (10), p.3256-3260 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433 |
---|---|
cites | cdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433 |
container_end_page | 3260 |
container_issue | 10 |
container_start_page | 3256 |
container_title | Nephrology, dialysis, transplantation |
container_volume | 25 |
creator | Slagman, Maartje C.J. Sinkeler, Steef J. Hemmelder, Marc H. Waanders, Femke Vogt, Liffert Kluin-Nelemans, Hanneke C. Navis, Gerjan Laverman, Gozewijn D. |
description | Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact. |
doi_str_mv | 10.1093/ndt/gfq149 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_755174677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>755174677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</originalsourceid><addsrcrecordid>eNpFkM1uFDEQhC1ERJbAhQdAvqBISEPs8fz5uFqFBGklFP6E9mJ57DZrMmtPbA9hXyFPjcNsklMf6uuq7kLoDSUfKOHszOl09svc0Io_QwtaNaQoWVc_R4ss0oLUhB-jlzH-JoTwsm1foOOSMMYJ5wt0dx72aRv86C0k67CNOICeFGjc77Hyu946max32Bus7RQypXDaQpDjHkun8Zfl8ivuB6-upQacLcbgE1g3hQwGcHLAY3YAlyK-tWmbdYgQ_uSEWTWTU_cJr9CRkUOE14d5gr5_PP-2uizWny8-rZbrQuWbU6H6suJdVXeGEl0r1umaAtX5IdlA0_Gm7DsDQJtSGuAlNbTqlaK9ZErpqmLsBJ3OvvnQmwliEjsbFQyDdOCnKNq6pm3VtG0m38-kCj7GAEaMwe5k2AtKxH31Ilcv5uoz_PZgO_U70I_oQ9cZeHcAZFRyMEE6ZeMTx1hDqv-pxczZmODvoy7DtWha1tbi8udGrH5s6HpzdZXX_gHkyZ_G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755174677</pqid></control><display><type>article</type><title>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</title><source>Oxford Journals Online</source><creator>Slagman, Maartje C.J. ; Sinkeler, Steef J. ; Hemmelder, Marc H. ; Waanders, Femke ; Vogt, Liffert ; Kluin-Nelemans, Hanneke C. ; Navis, Gerjan ; Laverman, Gozewijn D.</creator><creatorcontrib>Slagman, Maartje C.J. ; Sinkeler, Steef J. ; Hemmelder, Marc H. ; Waanders, Femke ; Vogt, Liffert ; Kluin-Nelemans, Hanneke C. ; Navis, Gerjan ; Laverman, Gozewijn D.</creatorcontrib><description>Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfq149</identifier><identifier>PMID: 20339099</identifier><identifier>CODEN: NDTREA</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Biological and medical sciences ; Cross-Over Studies ; diuretics ; Diuretics - administration & dosage ; Double-Blind Method ; Drug Therapy, Combination ; Emergency and intensive care: renal failure. Dialysis management ; erythropoietin ; Erythropoietin - blood ; Female ; haemoglobin ; Humans ; Hydrochlorothiazide - administration & dosage ; Intensive care medicine ; Kidney - physiopathology ; Losartan - administration & dosage ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; proteinuria ; Proteinuria - blood ; Proteinuria - drug therapy ; Proteinuria - physiopathology ; renal disease ; Renal failure ; renin–angiotensin–aldosterone system blockade</subject><ispartof>Nephrology, dialysis, transplantation, 2010-10, Vol.25 (10), p.3256-3260</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</citedby><cites>FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23360477$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20339099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slagman, Maartje C.J.</creatorcontrib><creatorcontrib>Sinkeler, Steef J.</creatorcontrib><creatorcontrib>Hemmelder, Marc H.</creatorcontrib><creatorcontrib>Waanders, Femke</creatorcontrib><creatorcontrib>Vogt, Liffert</creatorcontrib><creatorcontrib>Kluin-Nelemans, Hanneke C.</creatorcontrib><creatorcontrib>Navis, Gerjan</creatorcontrib><creatorcontrib>Laverman, Gozewijn D.</creatorcontrib><title>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol Dial Transplant</addtitle><description>Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Cross-Over Studies</subject><subject>diuretics</subject><subject>Diuretics - administration & dosage</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>erythropoietin</subject><subject>Erythropoietin - blood</subject><subject>Female</subject><subject>haemoglobin</subject><subject>Humans</subject><subject>Hydrochlorothiazide - administration & dosage</subject><subject>Intensive care medicine</subject><subject>Kidney - physiopathology</subject><subject>Losartan - administration & dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>proteinuria</subject><subject>Proteinuria - blood</subject><subject>Proteinuria - drug therapy</subject><subject>Proteinuria - physiopathology</subject><subject>renal disease</subject><subject>Renal failure</subject><subject>renin–angiotensin–aldosterone system blockade</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpFkM1uFDEQhC1ERJbAhQdAvqBISEPs8fz5uFqFBGklFP6E9mJ57DZrMmtPbA9hXyFPjcNsklMf6uuq7kLoDSUfKOHszOl09svc0Io_QwtaNaQoWVc_R4ss0oLUhB-jlzH-JoTwsm1foOOSMMYJ5wt0dx72aRv86C0k67CNOICeFGjc77Hyu946max32Bus7RQypXDaQpDjHkun8Zfl8ivuB6-upQacLcbgE1g3hQwGcHLAY3YAlyK-tWmbdYgQ_uSEWTWTU_cJr9CRkUOE14d5gr5_PP-2uizWny8-rZbrQuWbU6H6suJdVXeGEl0r1umaAtX5IdlA0_Gm7DsDQJtSGuAlNbTqlaK9ZErpqmLsBJ3OvvnQmwliEjsbFQyDdOCnKNq6pm3VtG0m38-kCj7GAEaMwe5k2AtKxH31Ilcv5uoz_PZgO_U70I_oQ9cZeHcAZFRyMEE6ZeMTx1hDqv-pxczZmODvoy7DtWha1tbi8udGrH5s6HpzdZXX_gHkyZ_G</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>Slagman, Maartje C.J.</creator><creator>Sinkeler, Steef J.</creator><creator>Hemmelder, Marc H.</creator><creator>Waanders, Femke</creator><creator>Vogt, Liffert</creator><creator>Kluin-Nelemans, Hanneke C.</creator><creator>Navis, Gerjan</creator><creator>Laverman, Gozewijn D.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20101001</creationdate><title>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</title><author>Slagman, Maartje C.J. ; Sinkeler, Steef J. ; Hemmelder, Marc H. ; Waanders, Femke ; Vogt, Liffert ; Kluin-Nelemans, Hanneke C. ; Navis, Gerjan ; Laverman, Gozewijn D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Angiotensin II Type 1 Receptor Blockers - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Cross-Over Studies</topic><topic>diuretics</topic><topic>Diuretics - administration & dosage</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>erythropoietin</topic><topic>Erythropoietin - blood</topic><topic>Female</topic><topic>haemoglobin</topic><topic>Humans</topic><topic>Hydrochlorothiazide - administration & dosage</topic><topic>Intensive care medicine</topic><topic>Kidney - physiopathology</topic><topic>Losartan - administration & dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>proteinuria</topic><topic>Proteinuria - blood</topic><topic>Proteinuria - drug therapy</topic><topic>Proteinuria - physiopathology</topic><topic>renal disease</topic><topic>Renal failure</topic><topic>renin–angiotensin–aldosterone system blockade</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slagman, Maartje C.J.</creatorcontrib><creatorcontrib>Sinkeler, Steef J.</creatorcontrib><creatorcontrib>Hemmelder, Marc H.</creatorcontrib><creatorcontrib>Waanders, Femke</creatorcontrib><creatorcontrib>Vogt, Liffert</creatorcontrib><creatorcontrib>Kluin-Nelemans, Hanneke C.</creatorcontrib><creatorcontrib>Navis, Gerjan</creatorcontrib><creatorcontrib>Laverman, Gozewijn D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slagman, Maartje C.J.</au><au>Sinkeler, Steef J.</au><au>Hemmelder, Marc H.</au><au>Waanders, Femke</au><au>Vogt, Liffert</au><au>Kluin-Nelemans, Hanneke C.</au><au>Navis, Gerjan</au><au>Laverman, Gozewijn D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol Dial Transplant</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>25</volume><issue>10</issue><spage>3256</spage><epage>3260</epage><pages>3256-3260</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><coden>NDTREA</coden><abstract>Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>20339099</pmid><doi>10.1093/ndt/gfq149</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0931-0509 |
ispartof | Nephrology, dialysis, transplantation, 2010-10, Vol.25 (10), p.3256-3260 |
issn | 0931-0509 1460-2385 |
language | eng |
recordid | cdi_proquest_miscellaneous_755174677 |
source | Oxford Journals Online |
subjects | Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Angiotensin II Type 1 Receptor Blockers - administration & dosage Biological and medical sciences Cross-Over Studies diuretics Diuretics - administration & dosage Double-Blind Method Drug Therapy, Combination Emergency and intensive care: renal failure. Dialysis management erythropoietin Erythropoietin - blood Female haemoglobin Humans Hydrochlorothiazide - administration & dosage Intensive care medicine Kidney - physiopathology Losartan - administration & dosage Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure proteinuria Proteinuria - blood Proteinuria - drug therapy Proteinuria - physiopathology renal disease Renal failure renin–angiotensin–aldosterone system blockade |
title | Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A20%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythropoietin%20is%20reduced%20by%20combination%20of%20diuretic%20therapy%20and%20RAAS%20blockade%20in%20proteinuric%20renal%20patients%20with%20preserved%20renal%20function&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Slagman,%20Maartje%20C.J.&rft.date=2010-10-01&rft.volume=25&rft.issue=10&rft.spage=3256&rft.epage=3260&rft.pages=3256-3260&rft.issn=0931-0509&rft.eissn=1460-2385&rft.coden=NDTREA&rft_id=info:doi/10.1093/ndt/gfq149&rft_dat=%3Cproquest_cross%3E755174677%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=755174677&rft_id=info:pmid/20339099&rfr_iscdi=true |